Increased fracture rate in women with breast cancer: a review of the hidden risk
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Increased fracture rate in women with breast cancer: a review of the hidden risk
Authors
Keywords
-
Journal
BMC CANCER
Volume 11, Issue 1, Pages -
Publisher
Springer Nature
Online
2011-08-30
DOI
10.1186/1471-2407-11-384
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Heparin versus Danaproid for Prevention of Venous Thromboembolism after Hip Surgery
- (2016) J Nakase et al. Journal of Orthopaedic Surgery
- Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
- (2010) H. Eidtmann et al. ANNALS OF ONCOLOGY
- Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
- (2010) Allan Lipton BREAST CANCER RESEARCH AND TREATMENT
- Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study
- (2010) Robert E. Coleman et al. BREAST CANCER RESEARCH AND TREATMENT
- A prospective study on socioeconomic aspects of fracture of the proximal femur
- (2010) M.-A. Schürch et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial
- (2010) Catherine Van Poznak et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
- Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
- (2009) M. Rabaglio et al. ANNALS OF ONCOLOGY
- Managing osteoporosis: Challenges and strategies
- (2009) E. M. LEWIECKI CLEVELAND CLINIC JOURNAL OF MEDICINE
- Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results
- (2009) Adam M. Brufsky et al. Clinical Breast Cancer
- Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women
- (2009) Dana Bliuc JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
- (2009) Michael Gnant et al. NEW ENGLAND JOURNAL OF MEDICINE
- Practical guidance for the management of aromatase inhibitor-associated bone loss
- (2008) P. Hadji et al. ANNALS OF ONCOLOGY
- Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group
- (2008) David M. Reid et al. CANCER TREATMENT REVIEWS
- Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer
- (2008) J. E. Lester et al. CLINICAL CANCER RESEARCH
- Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis
- (2008) Peyman Hadji CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
- (2008) Georgiana K. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now